The Current Ratio as of November 2024 (TTM) for Crinetics Pharmaceuticals, Inc. (CRNX) is 16.38

According to Crinetics Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 16.38. This represents a change of 3.61% compared to the average of 15.81 of the last 4 quarters.

Crinetics Pharmaceuticals, Inc. (CRNX) Historical Current Ratio (quarterly & annually)

How has CRNX Current Ratio performed in the past?

The mean historical Current Ratio of Crinetics Pharmaceuticals, Inc. over the last ten years is 16.33. The current 16.38 Current Ratio has changed 9.94% with respect to the historical average. Over the past ten years (40 quarters), CRNX's Current Ratio was at its highest in in the September 2018 quarter at 31.02. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Crinetics Pharmaceuticals, Inc. (CRNX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Crinetics Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Crinetics Pharmaceuticals, Inc. (CRNX) Average Current Ratio

How has CRNX Current Ratio performed in the past?

The current Current Ratio of Crinetics Pharmaceuticals, Inc. (CRNX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Crinetics Pharmaceuticals, Inc. (CRNX) Current Ratio vs. Peers

How is CRNX’s Current Ratio compared to its peers?

Crinetics Pharmaceuticals, Inc.’s Current Ratio is less than Viridian Therapeutics, Inc. (18.55), greater than Cytokinetics, Incorporated (9.28), less than Structure Therapeutics Inc. (27.63), less than Icosavax, Inc. (18.06), less than Passage Bio, Inc. (0), greater than REGENXBIO Inc. (5.15), greater than LianBio (3.05), greater than Kezar Life Sciences, Inc. (10.06), greater than Inhibrx Biosciences, Inc. (7.65), greater than Merus N.V. (4.70), greater than Lyell Immunopharma, Inc. (8.32), greater than Kronos Bio, Inc. (13.43), greater than Black Diamond Therapeutics, Inc. (8.32), greater than TCR2 Therapeutics Inc. (5.55), greater than Harpoon Therapeutics, Inc. (2.77), greater than Alector, Inc. (1.89), greater than null (3.29),

Build a custom stock screener for Crinetics Pharmaceuticals, Inc. (CRNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Crinetics Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Crinetics Pharmaceuticals, Inc. (CRNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Crinetics Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.